Amgen

Open: 236.82 Close: 239.74 Change: 2.92

We programmed an AI to read Internet. This is what it found out about Amgen.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, year, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen stock (NASDAQ: AMGN) has seen a substantial 23% rise this year, far better than the broader S&P500 index, which is down 18%. Amgen announced that it is buying Horizon Therapeutics for more than $26 billion. Pomerantz LLP is investigating claims on behalf.

Today's News

Amgen stock (NASDAQ: AMGN) has seen a substantial 23% rise this year, far better than the broader S&P500 index, which is down 18%. Amgen announced that it is buying Horizon Therapeutics for more than $26 billion. Amgen stock price has seen a 5% drop over the last five trading days. Amgen has been named as a Top 25 Dividend Giant by ETF Channel, with a whopping $20.37B worth of stock held by ETFs. Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (NASDAQ: AMGN) Amgen will report its first quarter financial results on April 27, 2023. Amgen launches AMJEVITA biosimilar to AbbVies Humira in the United States. Amgen reported revenue of $6.11 billion for the quarter, down 2% from a year earlier. Amgen SupportPlus Co-Pay Program helps eligible commercially insured patients pay for their out-ｿof-pocket prescription costs. $25 out of pocket cost for each dose of Prolia® (denosumab) and EVENITY® (romosozumab-aqqg) through Amgen supportPlus. The Amgen SupportPlus Co-Pay Card helps eligible patients cover out-of-pocket medication costs related to an Amgen supportPlus product, up to program limits. The offer is not valid for patients whose prescription is paid for in whole or in part. Amgen expects full-year earnings in the range of $17.60 to $18.70 per share. Amgen shares have fallen 8.5% since the beginning of the year. Amgen Inc. Patents Assigned to Amgen Inc. filed for Patent: April 25, 2023 Assignee: Amgen. Lawsuit seeks to recover losses on behalf of Amgen investors. Amgen raises 2023 revenue, eps outlook - marketwatch.com. Amgen Raises 2023 Revenue, EPS Outlook. Amgen is one of the largest independent biopharmaceutical companies in the world. Amgen Cuts 450 jobs in second round of Layoffs this year. Amgen to Present at the 33rd Annual Oppenheimer Healthcare Conference. Rosen Law Firm reminds purchasers of securities of Amgen Inc. If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114. Amgen Inc. reported Q1 FY23 sales of $6.11 billion, down 2% Y/Y, resulting from lower revenue from COVID-19 manufacturing collaboration, partially. Amgen raised 2023 revenue, EPS outlook.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, year, Inc, revenue, cost, stock, report, and the most common words in the summary are: amgen, stock, market, inc, price, news, amgn, . One of the sentences in the summary was: Amgen announced that it is buying Horizon Therapeutics for more than $26 billion. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #inc #price #news #amgn.